 Rangaswamy Govindarajan
Concepts (139)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 3 | 2016 | 162 | 0.730 |
Why?
| | Anus Neoplasms | 1 | 2018 | 26 | 0.560 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1043 | 0.480 |
Why?
| | Embolism | 1 | 2015 | 18 | 0.480 |
Why?
| | Bone Marrow Neoplasms | 1 | 2015 | 13 | 0.470 |
Why?
| | Gene Regulatory Networks | 1 | 2016 | 112 | 0.460 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 332 | 0.450 |
Why?
| | Tumor Lysis Syndrome | 1 | 2014 | 6 | 0.440 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 59 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 647 | 0.420 |
Why?
| | Pyrazoles | 1 | 2014 | 123 | 0.400 |
Why?
| | Pyrimidines | 1 | 2014 | 205 | 0.400 |
Why?
| | Angiogenesis Inhibitors | 2 | 2006 | 186 | 0.390 |
Why?
| | Clinical Trials as Topic | 5 | 2019 | 466 | 0.390 |
Why?
| | Salvage Therapy | 1 | 2013 | 138 | 0.380 |
Why?
| | Actinomycosis | 1 | 2012 | 10 | 0.380 |
Why?
| | Biliary Tract Diseases | 1 | 2012 | 14 | 0.380 |
Why?
| | Bile Duct Neoplasms | 1 | 2012 | 29 | 0.380 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 207 | 0.370 |
Why?
| | Prognosis | 6 | 2019 | 2118 | 0.350 |
Why?
| | Middle Aged | 13 | 2024 | 13419 | 0.350 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1112 | 0.340 |
Why?
| | Benzenesulfonates | 2 | 2011 | 10 | 0.340 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 212 | 0.330 |
Why?
| | Stroke | 1 | 2015 | 520 | 0.330 |
Why?
| | Pyridines | 2 | 2011 | 135 | 0.310 |
Why?
| | Liver Neoplasms | 1 | 2013 | 346 | 0.300 |
Why?
| | Colorectal Neoplasms | 2 | 2003 | 302 | 0.290 |
Why?
| | Aged, 80 and over | 6 | 2018 | 3494 | 0.270 |
Why?
| | Heparin | 1 | 2007 | 86 | 0.260 |
Why?
| | Drug Industry | 1 | 2007 | 39 | 0.260 |
Why?
| | Thrombocytopenia | 1 | 2007 | 89 | 0.250 |
Why?
| | Hypertensive Encephalopathy | 1 | 2006 | 3 | 0.250 |
Why?
| | raf Kinases | 1 | 2006 | 4 | 0.250 |
Why?
| | Communication Barriers | 1 | 2007 | 35 | 0.250 |
Why?
| | Thiazolidinediones | 1 | 2007 | 81 | 0.250 |
Why?
| | Aged | 10 | 2024 | 10429 | 0.250 |
Why?
| | Isoantigens | 1 | 2026 | 15 | 0.240 |
Why?
| | Oncolytic Virotherapy | 1 | 2026 | 28 | 0.240 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2026 | 43 | 0.240 |
Why?
| | Female | 13 | 2026 | 28782 | 0.230 |
Why?
| | Adult | 10 | 2024 | 14534 | 0.230 |
Why?
| | Thrombosis | 1 | 2007 | 250 | 0.220 |
Why?
| | Skin | 1 | 2007 | 419 | 0.220 |
Why?
| | Anticoagulants | 1 | 2007 | 280 | 0.220 |
Why?
| | CTLA-4 Antigen | 1 | 2024 | 32 | 0.220 |
Why?
| | Humans | 18 | 2026 | 53230 | 0.210 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 371 | 0.210 |
Why?
| | Immunotherapy | 1 | 2026 | 266 | 0.210 |
Why?
| | Tumor Microenvironment | 1 | 2026 | 274 | 0.210 |
Why?
| | Pancreatic Neoplasms | 1 | 2026 | 219 | 0.200 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 401 | 0.200 |
Why?
| | Survival Rate | 2 | 2018 | 949 | 0.200 |
Why?
| | Male | 11 | 2024 | 27435 | 0.190 |
Why?
| | Follow-Up Studies | 3 | 2019 | 2318 | 0.190 |
Why?
| | Camptothecin | 1 | 2002 | 14 | 0.180 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 71 | 0.180 |
Why?
| | Lung Neoplasms | 1 | 2007 | 645 | 0.170 |
Why?
| | Oximes | 1 | 2020 | 17 | 0.170 |
Why?
| | Pyrimidinones | 1 | 2020 | 19 | 0.170 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2007 | 591 | 0.160 |
Why?
| | Pyridones | 1 | 2020 | 38 | 0.160 |
Why?
| | Thalidomide | 1 | 2002 | 378 | 0.160 |
Why?
| | Imidazoles | 1 | 2020 | 114 | 0.160 |
Why?
| | Cholangiocarcinoma | 2 | 2011 | 27 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 233 | 0.140 |
Why?
| | Survival Analysis | 3 | 2020 | 659 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1232 | 0.130 |
Why?
| | Melanoma | 1 | 2020 | 277 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 640 | 0.120 |
Why?
| | Neoplasm Staging | 2 | 2013 | 774 | 0.120 |
Why?
| | Severity of Illness Index | 1 | 2019 | 1049 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 477 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2020 | 500 | 0.110 |
Why?
| | Gene Amplification | 1 | 2015 | 58 | 0.110 |
Why?
| | Adenine | 1 | 2014 | 29 | 0.110 |
Why?
| | Genes, myc | 1 | 2015 | 39 | 0.110 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2015 | 48 | 0.110 |
Why?
| | Retrospective Studies | 3 | 2018 | 6819 | 0.110 |
Why?
| | Piperidines | 1 | 2014 | 98 | 0.100 |
Why?
| | United States | 3 | 2019 | 5409 | 0.100 |
Why?
| | Gene Deletion | 1 | 2015 | 279 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2020 | 5595 | 0.100 |
Why?
| | Registries | 3 | 2007 | 652 | 0.100 |
Why?
| | Quinazolines | 1 | 2013 | 34 | 0.100 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 208 | 0.100 |
Why?
| | Actinomyces | 1 | 2012 | 12 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 868 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 73 | 0.090 |
Why?
| | Comorbidity | 2 | 2019 | 638 | 0.090 |
Why?
| | Gallbladder Neoplasms | 1 | 2011 | 7 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 238 | 0.090 |
Why?
| | Phenylurea Compounds | 2 | 2011 | 18 | 0.080 |
Why?
| | Niacinamide | 2 | 2011 | 24 | 0.080 |
Why?
| | Incidence | 2 | 2019 | 1085 | 0.080 |
Why?
| | Neoplasms | 1 | 2019 | 1334 | 0.070 |
Why?
| | Necrosis | 1 | 2007 | 169 | 0.070 |
Why?
| | Drugs, Investigational | 1 | 2007 | 14 | 0.070 |
Why?
| | Causality | 1 | 2007 | 53 | 0.060 |
Why?
| | Hospitals, University | 1 | 2007 | 75 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 1180 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2011 | 237 | 0.060 |
Why?
| | Confidence Intervals | 1 | 2007 | 158 | 0.060 |
Why?
| | Age Distribution | 1 | 2007 | 175 | 0.060 |
Why?
| | Probability | 1 | 2007 | 171 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2007 | 93 | 0.060 |
Why?
| | Medical Oncology | 1 | 2007 | 97 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 830 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 248 | 0.060 |
Why?
| | Patient Selection | 1 | 2007 | 273 | 0.060 |
Why?
| | Publication Bias | 1 | 2005 | 14 | 0.060 |
Why?
| | Editorial Policies | 1 | 2005 | 14 | 0.060 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2024 | 46 | 0.050 |
Why?
| | Adolescent | 2 | 2024 | 6907 | 0.050 |
Why?
| | Periodicals as Topic | 1 | 2005 | 63 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1367 | 0.050 |
Why?
| | Young Adult | 2 | 2024 | 4511 | 0.050 |
Why?
| | Risk Assessment | 1 | 2007 | 1368 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2026 | 1470 | 0.050 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2020 | 19 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2003 | 623 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 78 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2020 | 110 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 370 | 0.040 |
Why?
| | Trisaccharides | 1 | 2019 | 1 | 0.040 |
Why?
| | Premedication | 1 | 2019 | 17 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 1583 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 456 | 0.040 |
Why?
| | Antibodies | 1 | 2019 | 147 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2019 | 211 | 0.040 |
Why?
| | Prospective Studies | 1 | 2024 | 2411 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2003 | 477 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 187 | 0.030 |
Why?
| | Arkansas | 1 | 2003 | 2068 | 0.030 |
Why?
| | Mice | 1 | 2026 | 5982 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 266 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 505 | 0.020 |
Why?
| | Animals | 1 | 2026 | 13526 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2011 | 466 | 0.020 |
Why?
|
|
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|